SCHEMBL4973246

SCHEMBL4973246

CC(=O)c1cccc2ncn(CC(=O)Nc3ccc(F)c(F)c3)c12

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.66
HTT P42858 2/20 0.49
RXFP1 Q9HBX9 3/20 0.46
KMT2A Q03164 3/20 0.45
POLB P06746 2/20 0.45
LMNA P02545 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PKM P14618 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4978479 0.83 SMN1; SMN2 (0.66) SMN1; SMN2HTTRXFP1KMT2APOLB
SCHEMBL3042107 0.81 SMN1; SMN2 (0.64) SMN1; SMN2HTTKMT2APOLBLMNA
SCHEMBL4973402 0.81 TP53 (0.50) SMN1; SMN2HTTRXFP1KMT2APOLB
SCHEMBL3038969 0.80 SMN1; SMN2 (1.00) SMN1; SMN2HTTKMT2APOLBLMNA
SCHEMBL4977894 0.79 MAPT (0.56) SMN1; SMN2HTTRXFP1KMT2APOLB
SCHEMBL4976902 0.79 RXFP1 (0.49) SMN1; SMN2HTTRXFP1POLBLMNA
SCHEMBL4451021 0.77 SMN1; SMN2 (0.67) SMN1; SMN2HTTRXFP1KMT2APOLB
SCHEMBL4974004 0.77 RXFP1 (0.47) RXFP1POLBKDM4EMAPTTP53
SCHEMBL4976222 0.77 RXFP1 (0.47) SMN1; SMN2HTTRXFP1POLBLMNA
SCHEMBL14283223 0.76 SMN1; SMN2 (0.40) SMN1; SMN2HTTPOLBLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP claimed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO claimed
US-20080015222-A1 New Heterocyclic Amides ASTRAZENECA AB (SE) 2008-01-17 US disclosed
EP-1797067-A1 NEW HETEROCYCLIC AMIDES AstraZeneca AB (SE) 2007-06-20 EP disclosed
WO-2006033620-A1 NEW HETEROCYCLIC AMIDES ASTRAZENECA AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015222-A1 New Heterocyclic Amides AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 SMN1; SMN2 4341/4885HTT 552/4885RXFP1 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.